VIVIMEDLAB Share Price | Vivimed Labs Ltd Stock Analysis & Recommendation

Q: Why is Vivimed Labs Ltd falling/rising?

As of 05-Sep, Vivimed Labs Ltd's stock price is rising, currently at 6.67, which reflects a change of 0.13 or 1.99% increase. This upward movement comes after a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, it has outperformed the sector by 2.44% today. Despite this short-term rise, the stock has shown a significant decline over the year-to-date, with a drop of 62.17%, and a negative EBITDA of Rs. -154.63 crore indicates underlying financial struggles. The company has a high Debt to EBITDA ratio of -2.61 times, suggesting a low ability to service its debt, and its return on equity averages only 1.75%, indicating low profitability. Furthermore, investor participation has decreased sharply, with delivery volume falling by 95.98% against the 5-day average. Overall, while the stock is experiencing a temporary rise, the long-term fundamentals remain weak, which poses risks for investors.

Q: Who are in the management team of Vivimed Labs.?

The management team of Vivimed Labs includes the following individuals:1. Santosh Varalwar - Managing Director2. V Manohar Rao - Whole Time Director3. Subhash Varalwar - Non Executive Director4. Sandeep Varalwar - Whole Time Director5. S Raghunandan - Whole Time Director6. M Bhagvanth Rao - Non Executive Independent Director7. Nixon Patel - Non Executive Independent Director8. Umanath Varahabhotla - Non Executive Independent Director9. Yugandhar Kopparthi - Company Secretary & Compliance OfficerIf you need more specific information about any of these individuals or their roles, feel free to ask!

Q: What does Vivimed Labs. do?

Overview:Vivimed Labs Ltd is engaged in the manufacturing of specialty chemicals primarily for the personal care and cosmetic industry, pharmaceuticals, APIs, and formulations, operating within the pharmaceuticals and drugs industry as a micro-cap company.History:Vivimed Labs Ltd was incorporated in an unspecified year and has undergone no status changes. The latest quarterly results reported are for March 2026, showing net sales and profit figures.Financial Snapshot:Most recent Net Sales: 12 Cr (Quarterly Results - Mar 2026) Most recent Net Profit: -147 Cr (Quarterly Results - Mar 2026) Market-cap value: INR 60 Cr (Micro Cap)Key Metrics:P/E: N/A Industry P/E: 37 Dividend Yield: 0.00% Debt-Equity: -1.88 Return on Equity: 83.86% Price-to-Book: -0.28Contact Details:Address: Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403 Phone: 91-8482-232045 Email: yugandhar.kopparthi@vivimedlabs.com Website: http://www.vivimedlabs.com

Q: Who are the peers of the Vivimed Labs.?

Peers: The peers of Vivimed Labs. are Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Dr Reddy's Labs, ANG Lifesciences, Deccan Healthcar, Unick Fix-A-Form, and Parabolic Drugs.Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, and Dr Reddy's Labs, while Below Average management risk is found at Vivimed Labs., ANG Lifesciences, Deccan Healthcar, and Unick Fix-A-Form. Growth is Excellent at Sun Pharma.Inds., Good at Deccan Healthcar, Average at Torrent Pharma and Dr Reddy's Labs, and Below Average at Divi's Lab., Cipla, Vivimed Labs., ANG Lifesciences, Unick Fix-A-Form, and the rest. Capital Structure is Excellent at Sun Pharma.Inds., Divi's Lab., and Cipla, Good at Torrent Pharma and Deccan Healthcar, while Below Average is noted for Vivimed Labs., ANG Lifesciences, Unick Fix-A-Form, and the rest.Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.10%, while the peer with the lowest is Deccan Healthcar at -33.81%. Vivimed Labs.' 1-year return is not available for comparison. Additionally, peers with a negative six-month return include Vivimed Labs., Deccan Healthcar, and Unick Fix-A-Form.

Technical Trend Update: Vivimed Labs. witnessed a change in Technical Grade on 22 Sep 2026. Click here to discover latest technical change!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

47.17 k (26.03%) Volume

Shareholding (Mar 2026)

FII

1.64%

Held by 5 FIIs

DII

0.12%

Held by 0 DIIs

Promoter

7.57%

Which are the latest news on Vivimed Labs.?

24-Sep-2026

Vivimed Labs Ltd Locks at Upper Circuit With 1.49% Gain — Buyers Queue, Sellers Absent
Vivimed Labs Ltd Locks at Lower Circuit With 1.83% Loss — Sellers Queue, No Buyers in Sight

Why is Vivimed Labs Ltd falling/rising?

06-Sep-2026

As of 05-Sep, Vivimed Labs Ltd's stock price is rising to 6.67, reflecting a 1.99% increase after a trend reversal. However, the stock has declined 62.17% year-to-date, indicating weak long-term fundamentals and significant financial struggles.

View full answer

Who are in the management team of Vivimed Labs.?

01-Sep-2026

The management team of Vivimed Labs includes Santosh Varalwar (Managing Director), V Manohar Rao, Sandeep Varalwar, and S Raghunandan (Whole Time Directors), along with Subhash Varalwar (Non Executive Director) and several Non Executive Independent Directors: M Bhagvanth Rao, Nixon Patel, and Umanath Varahabhotla. Yugandhar Kopparthi serves as the Company Secretary & Compliance Officer.

View full answer

What does Vivimed Labs. do?

01-Sep-2026

Vivimed Labs Ltd manufactures specialty chemicals for the personal care, cosmetic, and pharmaceutical industries. As of March 2026, it reported net sales of 12 Cr and a net loss of 147 Cr, with a market cap of INR 60 Cr.

View full answer

Who are the peers of the Vivimed Labs.?

01-Sep-2026

Vivimed Labs. peers include Sun Pharma, Divi's Lab, Torrent Pharma, Cipla, Dr Reddy's Labs, ANG Lifesciences, Deccan Healthcar, Unick Fix-A-Form, and Parabolic Drugs. While Sun Pharma and Divi's Lab show excellent management and capital structures, Vivimed Labs. has below-average ratings in these areas and lacks a 1-year return for comparison.

View full answer

How big is Vivimed Labs.?

01-Sep-2026

As of 31st August, Vivimed Labs Ltd has a market capitalization of 60.00 Cr and reported net sales of 74.21 Cr, with a net loss of 176.57 Cr over the latest four quarters. The company's shareholder's funds are 39.42 Cr, and total assets amount to 988.35 Cr.

View full answer

Should I buy, sell or hold Vivimed Labs Ltd?

18-Jul-2026

When is the next results date for Vivimed Labs Ltd?

15-Jul-2026

The next results date for Vivimed Labs Ltd is 17 July 2026.

View full answer

Compare Vivimed Labs. with Similar Stocks

Dr Reddy's Labs Guj. Inject(Ker)Torrent Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Low ability to service debt as the company has a high Debt to EBITDA ratio of -2.61 times
The company has been able to generate a Return on Equity (avg) of 1.75% signifying low profitability per unit of shareholders funds

Flat results in Mar 26

Risky - Negative EBITDA

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 44 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.88

Return on Equity

83.86%

Price to Book

-0.21

Revenue and Profits:

Net Sales:

12 Cr

(Quarterly Results - Mar 2026)

Net Profit:

-147 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.29%

6 Months

-11.19%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

-50.42%

5 Years

-74.24%

Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Vivimed Labs Ltd Locks at Upper Circuit With 1.68% Gain — Buyers Queue, Sellers Absent

At Rs 5.45, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 1.68% on 24 Sep 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Vivimed Labs Ltd Locks at Upper Circuit With 1.49% Gain — Buyers Queue, Sellers Absent

At Rs 5.48, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 1.49% on 23 Sep 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Vivimed Labs Ltd Locks at Lower Circuit With 1.83% Loss — Sellers Queue, No Buyers in Sight

At Rs 5.37, sellers were still queuing — but there were no buyers willing to take the other side. Vivimed Labs Ltd locked at its lower circuit of 1.83% on 22 Sep 2026, with unfilled sell orders and a frozen price.

Read full news article

Announcements

Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors

08-Sep-2026 | Source : BSE

Committee of Creditors meeting on 10th September 2026

Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors

17-Aug-2026 | Source : BSE

6th COC meeting on 18th August 2026

Re- Lodgement Of Transfer Requests

22-Jul-2026 | Source : BSE

re-lodgement of transfer requests

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18

SPLITS

Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-41.90%

EBIT Growth (5y)

-200.66%

EBIT to Interest (avg)

-1.77

Debt to EBITDA (avg)

12.52

Net Debt to Equity (avg)

-1.88

Sales to Capital Employed (avg)

0.64

Tax Ratio

0.64%

Dividend Payout Ratio

Pledged Shares

15.18%

Institutional Holding

1.76%

ROCE (avg)

-19.44%

ROE (avg)

1.75%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.21

EV to EBIT

-2.43

EV to EBITDA

-2.85

EV to Capital Employed

2.38

EV to Sales

5.94

PEG Ratio

Dividend Yield

ROCE (Latest)

-97.72%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

15.1806

Mutual Funds

Held by 0 Schemes

FIIs

Held by 5 FIIs (1.64%)

Promoter with highest holding

Varalwar Sandeep (2.81%)

Highest Public shareholder

Kitara Piin 1102 (9.37%)

Individual Investors Holdings

68.75%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -35.08% vs -48.49% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -757.57% vs -274.89% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.55",
          "val2": "11.63",
          "chgp": "-35.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-137.01",
          "val2": "-11.22",
          "chgp": "-1,121.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.79",
          "val2": "0.94",
          "chgp": "-15.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-142.10",
          "val2": "-16.57",
          "chgp": "-757.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,814.70%",
          "val2": "-96.47%",
          "chgp": "-1,718.23%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.33",
          "val2": "119.63",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.88",
          "val2": "0.31",
          "chgp": "-5,867.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.17",
          "val2": "18.12",
          "chgp": "0.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.23",
          "val2": "-25.63",
          "chgp": "-72.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.95%",
          "val2": "0.26%",
          "chgp": "-19.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.07",
          "val2": "176.15",
          "chgp": "-14.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.01",
          "val2": "-6.98",
          "chgp": "-229.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "27.39",
          "val2": "29.70",
          "chgp": "-7.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.54",
          "val2": "-49.31",
          "chgp": "-26.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.33%",
          "val2": "-3.96%",
          "chgp": "-11.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is -39.80% vs -37.86% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is -452.16% vs 90.27% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "69.99",
          "val2": "116.27",
          "chgp": "-39.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-152.43",
          "val2": "-13.05",
          "chgp": "-1,068.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.17",
          "val2": "2.95",
          "chgp": "41.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-176.47",
          "val2": "-31.96",
          "chgp": "-452.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-217.79%",
          "val2": "-11.22%",
          "chgp": "-206.57%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

7.55

11.63

-35.08%

Operating Profit (PBDIT) excl Other Income

-137.01

-11.22

-1,121.12%

Interest

0.79

0.94

-15.96%

Exceptional Items

0.00

Standalone Net Profit

-142.10

-16.57

-757.57%

Operating Profit Margin (Excl OI)

-1,814.70%

-96.47%

-1,718.23%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -35.08% vs -48.49% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is -757.57% vs -274.89% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Consolidated) - Sep'22

Sep'22

Sep'21

Change(%)

Net Sales

94.33

119.63

-21.15%

Operating Profit (PBDIT) excl Other Income

-17.88

0.31

-5,867.74%

Interest

18.17

18.12

0.28%

Exceptional Items

0.00

Consolidate Net Profit

-44.23

-25.63

-72.57%

Operating Profit Margin (Excl OI)

-18.95%

0.26%

-19.21%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021

Consolidated Net Profit

Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021

All Half Yearly Results

Nine Monthly Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

150.07

176.15

-14.81%

Operating Profit (PBDIT) excl Other Income

-23.01

-6.98

-229.66%

Interest

27.39

29.70

-7.78%

Exceptional Items

0.00

Consolidate Net Profit

-62.54

-49.31

-26.83%

Operating Profit Margin (Excl OI)

-15.33%

-3.96%

-11.37%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021

Consolidated Net Profit

YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

69.99

116.27

-39.80%

Operating Profit (PBDIT) excl Other Income

-152.43

-13.05

-1,068.05%

Interest

4.17

2.95

41.36%

Exceptional Items

0.00

Consolidate Net Profit

-176.47

-31.96

-452.16%

Operating Profit Margin (Excl OI)

-217.79%

-11.22%

-206.57%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is -39.80% vs -37.86% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is -452.16% vs 90.27% in Mar 2025

All Annual Results

Company CV

About Vivimed Labs Ltd

Vivimed Labs Ltd

Micro Cap

Pharmaceuticals & Drugs

Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.